MRUS News and Press, Merus N.V. From 12/10/21

Merus (NASDAQ:MRUS) presents clinical data on zenocutuzumab (Zeno) in combination with trastuzumab and vinorelbine in patients with HER2+ metastatic breast cancer (MBC) at the San Antonio Breast Cancer Symposium in San Antonio, Texas. The primary endpoint of clinical benefit rate (CBR) at 24 ...

- The primary endpoint of Clinical Benefit Rate at 24 weeks with the triplet combination was met - The triplet combination showed clinically meaningful activity after 3 lines of anti-HER2 therapies including T-DM1 - Validates the potential of zenocutuzumab in additional indication...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific ant...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific ant...

Merus (NASDAQ:MRUS) has priced its offering of 3.86M shares of common stock at $28.50/share, for expected gross proceeds of ~$110.0M. Underwriters' over-allotment is an additional 578,947 shares. All of the shares in the offering are to be sold by Merus. Net proceeds ...

Merus (NASDAQ:MRUS) launched a underwritten public offering of shares; underwriters granted 30-day option to purchase an additional 15% of the shares. Offer size, terms have not yet been disclosed. Net proceeds to be used for advancing the clinical development of its product candida...

Shares of Merus N.V. (NASDAQ:MRUS) traded at a new 52-week high today of $32.90. This new high was reached on above average trading volume as 1.2 million shares traded hands, while the average 30-day volume is approximately 847,000 shares. Merus NV is a clinical-stage immuno-oncology com...

Merus participated in a Type B meeting with the FDA regarding its zenocutuzumab development program and obtained alignment with FDA on registration approach for a potential tumor agnostic indication Merus presented early clinical data on MCLA-158 at the AACR-NCI-EORTC Virtual In...

Shares of Merus N.V. (NASDAQ:MRUS) traded today at $31.66, eclipsing its 52-week high. So far today approximately 1.2 million shares have been exchanged, as compared to an average 30-day volume of 737,000 shares. In the past 52 weeks, Merus N.V. share prices are bracketed by a low of $11...

While the S&P 500 index eked out a ~0.8% gain over the week, its healthcare constituents slipped ~0.3% to record the fifth consecutive weekly loss. Dragged down by biotech stocks, the sector became the second-worst performer in the index. Among healthcare stocks with more than $...